![Peter Collins](https://profiles-cardiff.imgix.net/attachments/2403?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Peter Collins
Teams and roles for Peter Collins
Professor of Haematology
Overview
My research focuses on the diagnosis and treatment of inherited and acquired bleeding disorders. The work spans both clinical studies and basic science and I collaborate with a number of groups at Cardiff and across the world.
My clinical work is based in the Cardiff Haemophilia Centre and involves treating people with inherited and acquired disorders of haemostasis and thrombosis.
Publication
2025
- Bell, S. F. et al. 2025. Relationship between the dual platelet‐inhibited ROTEM ® Sigma FIBTEM assay and Clauss fibrinogen during postpartum haemorrhage. Anaesthesia: Peri-operative medicine, critical care and pain 80 (1), pp.104-106. (10.1111/anae.16455)
- Collins, P. W. and Thachil, J. 2025. Acquired coagulation disorders. In: Mead, A. J. et al., Hoffbrand's Postgraduate Haematology. Wiley. , pp.829-847. (10.1002/9781119706687.ch43)
- Collins, P. W. et al. 2025. Acute obstetric coagulopathy is associated with excess plasmin generation and proteolysis of fibrinogen and factor V. Blood Advances 9 (11), pp.2751-2762. (10.1182/bloodadvances.2024015514)
- Costa, D. O. et al. 2025. Circulating membrane aminophospholipids contribute to thrombotic risk in rheumatoid arthritis.. Journal of Lipid Research 66 (7) 100842. (10.1016/j.jlr.2025.100842)
- Morgan, B. et al. 2025. Pro-Coagulant Lipids in Physiological Ratios Found in the Activated Platelet Membrane Do Not Impact Clot Structure or Fibrinolysis in Purified Assays. Journal of Blood Medicine 16 , pp.509-521. (10.2147/jbm.s527558)
- Protty, M. B. et al. 2025. Aspirin modulates generation of procoagulant phospholipids in cardiovascular disease, by regulating LPCAT3.. Journal of Lipid Research 66 (1) 100727. (10.1016/j.jlr.2024.100727)
- Rai, T. et al., 2025. Managing obstetric bleeding in Wales: a qualitative evaluation of the OBS Cymru care bundle using normalisation process theory. PLoS One 20 (4) e0320754. (10.1371/journal.pone.0320754)
- Van Netten, C. et al., 2025. Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis. BMJ Open 15 (5) e101255. (10.1136/bmjopen-2025-101255)
- Wall, C. et al., 2025. Emicizumab utilisation, safety and outcomes in people with severe haemophilia and no inhibitors: Three years follow-up. A report from the UK Haemophilia Centre Doctors’ Organisation. Research and Practice in Thrombosis and Haemostasis 9 (6) 103164. (10.1016/j.rpth.2025.103164)
2024
- Diguisto, C. et al., 2024. Management and outcomes of women with low fibrinogen concentration during pregnancy or immediately postpartum: A UK national population‐based cohort study. Acta Obstetricia et Gynecologica Scandinavica 103 (7), pp.1339-1347. (10.1111/aogs.14828)
- Elsmore, A. et al., 2024. The OBS UK Dashboard: an interactive tool for representative trial site selection to facilitate equality and diversity in maternity research. Trials 25 629. (10.1186/s13063-024-08487-x)
- Hajeyah, A. A. et al. 2024. Phosphatidylthreonine is a procoagulant lipid detected in human blood and elevated in coronary artery disease.. Journal of Lipid Research 65 (1) 100484. (10.1016/j.jlr.2023.100484)
- Koopman, S. F. et al., 2024. A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B. British Journal of Clinical Pharmacology 90 (1), pp.220-231. (10.1111/bcp.15881)
- Pipe, S. W. et al., 2024. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 14 , pp.1355-1364. (10.1182/blood.2023021832)
- Protty, M. B. et al. 2024. Thrombin generation is associated with extracellular vesicle and leukocyte lipid membranes in atherosclerotic cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 44 (9), pp.2038-2052. (10.1161/ATVBAHA.124.320902)
2023
- Bell, S. F. et al. 2023. Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.03.029)
- de Lloyd, L. et al. 2023. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. Journal of Thrombosis and Haemostasis 21 (4), pp.862-879. (10.1016/j.jtha.2022.11.036)
- Wall, C. et al., 2023. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO). Haemophilia 29 (3)(10.1111/hae.14762)
- Zwagemaker, A. et al., 2023. Little discrepancy between one-stage and chromogenic FVIII/IX assays in a large international cohort of persons with non-severe hemophilia A and B. Journal of Thrombosis and Haemostasis 21 (4), pp.850-861. (10.1016/j.jtha.2022.11.040)
2022
- Bell, S. .. , Collis, R. E. and Collins, P. W. 2022. Comparison of haematological indices and transfusion management in severe and massive postpartum haemorrhage: analysis of a two-year national prospective observational study. International Journal of Obstetric Anesthesia 50 103547. (10.1016/j.ijoa.2022.103547)
- Bell, S. et al. 2022. The sensitivity and specificity of rotational thromboelastometry (ROTEM) to detect coagulopathy during moderate and severe postpartum haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia 49 103238. (10.1016/j.ijoa.2021.103238)
- Dale, M. et al. 2022. What is the economic cost of providing an all Wales postpartum haemorrhage quality improvement initiative (OBS Cymru)? A cost-consequences comparison with standard care. PharmacoEconomics - Open 6 , pp.847-857. (10.1007/s41669-022-00362-2)
- Dixon, P. H. et al., 2022. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements. Nature Communications 13 (1) 4840. (10.1038/s41467-022-29931-z)
- Kloosterman, F. R. et al., 2022. The bleeding phenotype in people with nonsevere hemophilia. Blood Advances 6 (14), pp.4256-4265. (10.1182/bloodadvances.2022007620)
- Powell, E. et al., 2022. Introduction of standardized, cumulative quantitative measurement of blood loss into routine maternity care. Journal of Maternal-Fetal and Neonatal Medicine 35 (8), pp.1491-1497. (10.1080/14767058.2020.1759534)
- Protty, M. B. et al. 2022. The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis. Open Biology 12 (4) 210318. (10.1098/rsob.210318)
- Torabi, F. et al., 2022. Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales. Scientific Reports 12 16406. (10.1038/s41598-022-20118-6)
- Van Der Valk, P. et al., 2022. Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances 6 (3), pp.902-908. (10.1182/bloodadvances.2021005260)
2021
- Bell, S. F. et al., 2021. The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. International Journal of Obstetric Anesthesia 47 102983. (10.1016/j.ijoa.2021.102983)
- Bell, S. F. et al. 2021. Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study. BMC Pregnancy and Childbirth 21 377. (10.1186/s12884-021-03853-y)
- Bell, S. F. et al. 2021. Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study (October 11, 2020). Working paper. SSRN: SSRN. Available at: http://doi.org/10.2139/ssrn.3746928.
- Bukkems, L. H. et al., 2021. Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease. Blood Advances 5 (5), pp.1513-1522. (10.1182/bloodadvances.2020003891)
- Collins, P. W. et al. 2021. Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?. Haemophilia 27 (2), pp.192-198. (10.1111/hae.14201)
- Kemp, A. M. et al. 2021. Can TEN4 distinguish bruises from abuse, inherited bleeding disorders or accidents?. Archives of Disease in Childhood 106 (8), pp.774-779. (10.1136/archdischild-2020-320491)
- Klamroth, R. et al., 2021. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood 137 (13), pp.1818–1827. (10.1182/blood.2020005673)
- Krishnaswamy, S. et al., 2021. Illustrated state-of-the-art capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis 5 (5) e12532. (10.1002/rth2.12532)
- Olasupo, O. O. et al., 2021. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Cochrane Library 2021 (8) CD014201. (10.1002/14651858.CD014201)
- Roberts, T. C. D. et al., 2021. Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia 47 103192. (10.1016/j.ijoa.2021.103192)
2020
- Bell, S. F. et al., 2020. Incidence of postpartum haemorrhage defined by quantitative blood loss measurement: a national cohort. BMC Pregnancy and Childbirth 20 (1) 271. (10.1186/s12884-020-02971-3)
- Bury, L. et al., 2020. Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Human Mutation 41 (1), pp.277-290. (10.1002/humu.23927)
- Chowdary, P. et al., 2020. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. Thrombosis and Haemostasis 120 (05), pp.728-736. (10.1055/s-0040-1709519)
- Rosas, M. et al. 2020. The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles. PLoS ONE 15 (10) e0240189. (10.1371/journal.pone.0240189)
- Tiede, A. et al., 2020. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A. Haemophilia 26 (1), pp.47-55. (10.1111/hae.13878)
2019
- Allen-Redpath, K. et al. 2019. Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity. Proceedings of the National Academy of Sciences 116 (16), pp.8038-8047. (10.1073/pnas.1814409116)
- Collins, P. W. et al. 2019. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. International Journal of Obstetric Anesthesia 37 , pp.106-117. (10.1016/j.ijoa.2018.08.008)
- Gorman, K. M. et al., 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104 (5), pp.948-956. (10.1016/j.ajhg.2019.03.005)
- Scott, M. J. et al., 2019. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia -Oxford- 25 (2), pp.205-212. (10.1111/hae.13616)
2018
- Baaten, C. C. F. M. J. et al., 2018. Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Advances 2 (18), pp.2320-2331. (10.1182/bloodadvances.2017011544)
- Chalmers, E. A. et al., 2018. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: a national cohort study. Haemophilia 24 (4), pp.641-647. (10.1111/hae.13461)
- Chowdary, P. et al., 2018. Retrospective review of a Prothrombin Complex Concentrate (Beriplex P/N) for the management of perioperative bleeding unrelated to oral anticoagulation. Clinical and Applied Thrombosis/Hemostasis 24 (7), pp.1159-1169. (10.1177/1076029617753537)
- Collins, P. W. et al. 2018. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia 24 (1), pp.104-112. (10.1111/hae.13324)
- Collins, P. W. et al. 2018. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 24 (3), pp.344-347. (10.1111/hae.13495)
- Curry, N. S. et al., 2018. The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology 182 (6), pp.789-806. (10.1111/bjh.15524)
- Hazendonk, H. C. A. M. et al., 2018. Perioperative replacement therapy in haemophilia B: an appeal to "B" more precise. Haemophilia 24 (4), pp.611-618. (10.1111/hae.13469)
- Hazendonk, H. et al., 2018. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?. Blood Reviews 32 (4), pp.265-271. (10.1016/j.blre.2018.01.001)
- Iorio, A. et al., 2018. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2 (3), pp.535-548. (10.1002/rth2.12106)
- Mathias, M. C. et al., 2018. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia 24 (6), pp.896-901. (10.1111/hae.13551)
- Meher, S. et al., 2018. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: An International Journal of Obstetrics & Gynaecology (10.1111/1471-0528.15335)
- Preijers, T. et al., 2018. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostatis 16 (11), pp.2196-2207. (10.1111/jth.14292)
- Slatter, D. A. et al. 2018. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight 3 (6) e98459. (10.1172/jci.insight.98459)
- Whitworth, J. et al., 2018. Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes. American Journal of Human Genetics 103 (1), pp.3-18. (10.1016/j.ajhg.2018.04.013)
2017
- Aldrovandi, M. et al. 2017. DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biology 11 , pp.663-672. (10.1016/j.redox.2017.01.001)
- Collins, P. W. et al. 2017. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. British Journal of Anaesthesia 119 (3), pp.411-421. (10.1093/bja/aex181)
- Collins, P. W. et al. 2017. Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. British Journal of Anaesthesia 119 (3), pp.422-434. (10.1093/bja/aex245)
- Hay, C. R. M. et al., 2017. The haemtrack home therapy reporting system: design, implementation, strengths and weaknesses: a report from UK Haemophilia Centre Doctors Organisation. Haemophilia 23 (5), pp.728-735. (10.1111/hae.13287)
- Iorio, A. et al., 2017. Estimating and interpreting individual patients' pharmacokinetic profiles in persons with Hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 15 (12), pp.2461-2465. (10.1111/jth.13867)
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10 (507) eaan2787. (10.1126/scisignal.aan2787)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2 (1)(10.12688/wellcomeopenres.10308.1)
- Peyvandi, F. et al., 2017. Minimal dataset for post-registration surveillance of new drugs in haemophilia: communication from the SSC or the ISTH. Journal of Thrombosis and Haemostatis 15 (9), pp.1878-1881. (10.1111/jth.13762)
- Pleines, I. et al., 2017. Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. The Journal of Clinical Investigation 127 (3), pp.814-829. (10.1172/JCI86154)
- Schöchl, H. et al., 2017. Theoretical modeling of coagulation management with therapeutic plasma or prothrombin complex concentrate. Anesthesia and Analgesia 125 (5), pp.1471-1474. (10.1213/ANE.0000000000002410)
- Trickey, R. C. et al. 2017. Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development post-surgery. Haemophilia 23 (3), pp.e234-e235. (10.1111/hae.13216)
- Uderhardt, S. et al., 2017. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis and thrombotic disease. Journal of Experimental Medicine 214 (7), pp.2121-2138. (10.1084/jem.20161070)
2016
- Bruynseels, D. et al. 2016. Commentary on reconstituting fibrinogen concentrate to maintain blinding in a double-blind, randomized trial in an emergency Setting. Journal of Emergency Medicine 28 (1), pp.104-107.e.1. (10.1016/j.jemermed.2015.09.017)
- Collins, P. et al. 2016. Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study. Archives of Disease in Childhood , pp.401-413. (10.1136/archdischild-2015-310196)
- Fischer, K. et al., 2016. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 14 (5), pp.1105-1109. (10.1111/jth.13298)
- Green, L. et al., 2016. The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. BJOG: An International Journal of Obstetrics & Gynaecology 123 (13), pp.2164-2170. (10.1111/1471-0528.13831)
- Green, L. et al., 2016. The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. British Journal of Haematology 172 (4), pp.616-624. (10.1111/bjh.13864)
- Heurich-Sevcenco, M. et al. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145 , pp.84-92. (10.1016/j.thromres.2016.07.017)
- Hinz, C. et al. 2016. Human platelets utilize cycloxygenase-1 to generate dioxolane A3, a neutrophil activating eicosanoid. Journal of Biological Chemistry 291 (26), pp.13448-13464. (10.1074/jbc.M115.700609)
- Johnson, B. et al., 2016. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica 101 (10), pp.1170-1179. (10.3324/haematol.2016.146316)
- Jones, R. M. et al., 2016. Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia 71 (6), pp.648-656. (10.1111/anae.13448)
- Lock, J. et al., 2016. Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia 22 (1) e1. (10.1111/hae.12851)
- Mattheij, N. J. et al., 2016. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling and swelling. Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde 41 (3), pp.207-208.
- Mattheij, N. J. A. et al., 2016. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. The FASEB Journal 30 (2), pp.727-737. (10.1096/fj.15-280446)
- Mauguière, F. A. L. et al., 2016. Toward understanding the roaming mechanism in H + MgH → Mg + HH reaction. Journal of Physical Chemistry A 120 (27), pp.5145-5154. (10.1021/acs.jpca.6b00682)
- Obaji, S. et al. 2016. Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia 22 (2), pp.285-291. (10.1111/hae.12811)
- Simeoni, I. et al., 2016. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 127 (23), pp.2791-2803. (10.1182/blood-2015-12-688267)
- Solari, F. A. et al., 2016. Combined quantification of the global proteome, phosphoproteome, and proteolytic cleavage to characterize altered platelet functions in the human Scott syndrome. Molecular & Cellular Proteomics 15 (10), pp.3154-3169. (10.1074/mcp.M116.060368)
- Stritt, S. et al., 2016. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood 127 (23), pp.2903-2914. (10.1182/blood-2015-10-675629)
- Swieringa, F. et al., 2016. Platelet control of fibrin distribution and microelasticity in thrombus formation under flow. Arteriosclerosis Thrombosis and Vascular Biology 36 (4), pp.692-699. (10.1161/ATVBAHA.115.306537)
- Turro, E. et al., 2016. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Science Translational Medicine 8 (328) 328ra30. (10.1126/scitranslmed.aad7666)
- Valentino, L. A. et al., 2016. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 22 (4), pp.514-520. (10.1111/hae.12905)
- Young, G. et al., 2016. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thrombosis Research 141 , pp.69-76. (10.1016/j.thromres.2016.02.030)
2015
- Aawar, N. et al. 2015. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials 16 (1), pp.1-11. (10.1186/s13063-015-0670-9)
- Agbani, E. O. et al., 2015. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation 132 (15), pp.1414-1424. (10.1161/CIRCULATIONAHA.114.015036)
- Collins, P. W. , Abdul-Kadir, R. and Thachil, J. 2015. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 14 (1), pp.205-210. (10.1111/jth.13174)
- Fletcher, S. J. et al., 2015. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. The Journal of Clinical Investigation 125 (9), pp.3600-3605. (10.1172/JCI80347)
- Hay, C. R. M. et al., 2015. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 21 (2), pp.219-226. (10.1111/hae.12563)
- Kemp, A. M. et al. 2015. Patterns of bruising in preschool children - a longitudinal study. Archives of Disease in Childhood 100 (5), pp.426-431. (10.1136/archdischild-2014-307120)
- Lilley, G. et al., 2015. Measurement of blood loss during postpartum haemorrhage. International Journal of Obstetric Anesthesia 24 (1), pp.8-14. (10.1016/j.ijoa.2014.07.009)
- Mahdi, A. J. , Obaji, S. and Collins, P. W. 2015. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. British Journal of Haematology 169 (6), pp.768-776. (10.1111/bjh.13360)
- Obaji, S. et al. 2015. Selective angiographic embolization for recurrent elbow and knee haemarthroses in haemophilia: a retrospective case series. Haemophilia 21 (3), pp.e226-e228. (10.1111/hae.12629)
- Percy, C. L. et al., 2015. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass. Blood Coagulation and Fibrinolysis 26 (4), pp.357-367. (10.1097/MBC.0000000000000243)
2014
- Batty, P. et al., 2014. A national survey of immunosuppression strategies for acquired haemophilia A. Haemophilia 21 (1), pp.e73-e76. (10.1111/hae.12547)
- Collins, P. W. et al. 2014. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 124 (11), pp.1727-1736. (10.1182/blood-2014-04-567891)
- Collins, P. W. et al. 2014. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe haemophilia A, 2000-2011. Blood 124 (23), pp.3389-3397. (10.1182/blood-2014-07-580498)
- Collins, P. W. et al. 2014. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 124 (26), pp.3880-3886. (10.1182/blood-2014-05-573055)
- Kemp, A. M. et al. 2014. Bruising in children who are assessed for suspected physical abuse. Archives of Disease in Childhood 99 , pp.108-113. (10.1136/archdischild-2013-304339)
- Khanum, F. et al., 2014. Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay. Haemophilia 20 (2), pp.287-293. (10.1111/hae.12272)
- Thomas, C. P. et al. 2014. Identification and quantification of aminophospholipid molecular species on the surface of apoptotic and activated cells. Nature Protocols 9 (1), pp.51-63. (10.1038/nprot.2013.163)
2013
- Aldrovandi, M. et al. 2013. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. Journal of Lipid Research 54 (11), pp.3085-3097. (10.1194/jlr.M041533)
- Bjorkman, S. and Collins, P. W. 2013. Measurement of factor VIII pharmacokinetics in routine clinical practice. Journal of Thrombosis and Haemostatis 11 (1), pp.180-182. (10.1111/jth.12055)
- Clark, S. R. et al. 2013. Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proceedings of the National Academy of Sciences of the United States of America 110 (15), pp.5875-5880. (10.1073/pnas.1222419110)
- Collins, P. W. et al. 2013. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)[note]. British Journal of Haematology 160 (2), pp.153-170. (10.1111/bjh.12091)
- Collins, P. W. et al. 2013. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. British Journal of Haematology 162 (6), pp.758-773. (10.1111/bjh.12463)
- Fransen van de Putte, D. E. et al., 2013. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis 109 (01), pp.16-23. (10.1160/TH12-05-0332)
- Lane, J. et al., 2013. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics 22 (9), pp.1903-1910. (10.1093/hmg/ddt033)
- Saunders, C. et al., 2013. Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma. Vox Sanguinis 105 (1), pp.1-10. (10.1111/vox.12013)
- Stockley, J. et al., 2013. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood 122 (25), pp.4090-4093. (10.1182/blood-2013-06-506873)
2012
- Baudo, F. et al., 2012. Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry. Blood 120 (1), pp.39-46. (10.1182/blood-2012-02-408930)
- Bjorkman, S. et al., 2012. Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight. Blood 119 (2), pp.612-618. (10.1182/blood-2011-07-360594)
- Collins, P. W. 2012. Personalized prophylaxis. Haemophilia 18 (s4), pp.131-135. (10.1111/j.1365-2516.2012.02838.x)
- Collins, P. W. et al. 2012. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood 120 (1), pp.47-55. (10.1182/blood-2012-02-409185)
- Collins, P. W. et al. 2012. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. Journal of Thrombosis and Haemostatis 10 (11), pp.2305-2312. (10.1111/jth.12000)
- Davies, J. A. et al. 2012. von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom [Letter]. Haemophilia 18 (3), pp.e79-e81. (10.1111/j.1365-2516.2012.02782.x)
- Fransen Van De Putte, D. et al., 2012. Cardiovascular disease history and risk factors in hemophilia patients [Abstract]. Haemophilia 18 (s3), pp.4-5. (10.1111/j.1365-2516.2012.02820.x)
- Knoebl, P. et al., 2012. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostatis 10 (4), pp.622-631. (10.1111/j.1538-7836.2012.04654.x)
- Tengborn, L. et al., 2012. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG: An International Journal of Obstetrics & Gynaecology 119 (12), pp.1529-1537. (10.1111/j.1471-0528.2012.03469.x)
2011
- Berntorp, E. et al., 2011. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 17 (1), pp.e202-e210. (10.1111/j.1365-2516.2010.02377.x)
- Castoldi, E. et al., 2011. P-MO-061 Identification of two novel TMEM16F mutations in a patient with scott syndrome [Abstract]. Journal of Thrombosis and Haemostatis 9 (s2), pp.77. (10.1111/j.1538-7836.2011.04380_1.x)
- Coakley, M. et al. 2011. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. Journal of Thrombosis and Haemostatis 9 (2), pp.282-292. (10.1111/j.1538-7836.2010.04146.x)
- Collins, P. W. 2011. Management of acquired haemophilia A. Journal of Thrombosis and Haemostatis 9 (Supp 1), pp.226-235. (10.1111/j.1538-7836.2011.04309.x)
- Collins, P. W. et al. 2011. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17 (1), pp.2-10. (10.1111/j.1365-2516.2010.02370.x)
- De Lloyd, L. et al. 2011. Standard haemostatic tests following major obstetric haemorrhage. International Journal of Obstetric Anesthesia 20 (2), pp.135-141. (10.1016/j.ijoa.2010.12.002)
- di Mambro, A. J. et al., 2011. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53 (4), pp.1316-1322. (10.1002/hep.24159)
- Hay, C. R. M. et al., 2011. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 117 (23), pp.6367-6370. (10.1182/blood-2010-09-308668)
2010
- Bell, S. F. et al. 2010. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. International Journal of Obstetric Anesthesia 19 (2), pp.218-223. (10.1016/j.ijoa.2009.08.004)
- Bjorkman, S. et al., 2010. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostatis 8 (4), pp.730-736. (10.1111/j.1538-7836.2010.03757.x)
- Collins, P. W. 2010. Pharmacokinetic approaches to prophylaxis [Abstract]. Haemophilia 16 (2), pp.396. (10.1111/j.1365-2516.2010.02182.x)
- Collins, P. W. et al. 2010. Announcement: Non-malignant haematology research in the UK: looking forward to new opportunities. British Journal of Haematology 150 (6), pp.732-736. (10.1111/j.1365-2141.2010.08384.x)
- Collins, P. W. et al. 2010. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes 3 161. (10.1186/1756-0500-3-161)
- Collins, P. W. et al. 2010. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostatis 8 (2), pp.269-275. (10.1111/j.1538-7836.2009.03703.x)
- Collins, P. W. et al. 2010. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. Journal of Thrombosis and Haemostatis 8 (1), pp.83-89. (10.1111/j.1538-7836.2009.03650.x)
- Collins, P. W. and Percy, C. L. 2010. Advances in the understanding of acquired haemophilia A: implications for clinical practice. British Journal of Haematology 148 (2), pp.183-194. (10.1111/j.1365-2141.2009.07915.x)
- Oh, M. et al. 2010. The effect of reduced sampling time points in a population pharmacokinetic model of ADVATE in pediatric and adult patients with hemophilia A [Abstract]. Haemophilia -Oxford- 16 (S4), pp.38-39. (10.1111/j.1365-2516.2010.02283.x)
- Thomas, C. P. et al. 2010. Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. Journal of Biological Chemistry 285 (10), pp.6891-6903. (10.1074/jbc.M109.078428)
2009
- Collins, P. W. et al. 2009. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostatis 7 (3), pp.413-420. (10.1111/j.1538-7836.2008.03270.x)
- Collins, P. W. et al. 2009. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostatis 7 (5), pp.787-794. (10.1111/j.1538-7836.2009.03332.x)
- Huth-Kuhne, A. et al., 2009. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 94 (4), pp.566-575. (10.3324/haematol.2008.001743)
- Percy, C. L. et al. 2009. Laboratory monitoring of Scott Syndrome. British Journal of Haematology 149 (6), pp.803. (10.1111/j.1365-2141.2009.07935.x)
- Shapiro, A. et al., 2009. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opinion on Biological Therapy 9 (3), pp.273-283. (10.1517/14712590902729392)
- Sutherland, M. S. et al., 2009. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood 114 (5), pp.1091-1098. (10.1182/blood-2008-08-173278)
- Wielders, S. J. H. et al., 2009. Absence of platelet-dependent fibrin formation in a patient with Scott syndrome. Thrombosis and Haemostasis 102 (1), pp.76-82. (10.1160/TH08-11-0719)
2008
- Collins, P. W. 2008. 01 S 01 Overview of acquired haemophilia A [Abstract]. Haemophilia 14 (S2), pp.1. (10.1111/j.1365-2516.2008.01725.x)
- Collins, P. W. et al. 2008. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 14 (s3), pp.49-55. (10.1111/j.1365-2516.2008.01745.x)
- Collins, P. W. et al. 2008. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 14 (4), pp.685-696. (10.1111/j.1365-2516.2008.01757.x)
- Moore, G. et al., 2008. 31 FP 05 Management of von Willebrand disease in the peripartum period - a UK based survey [Abstract]. Haemophilia 14 (S2), pp.155. (10.1111/j.1365-2516.2008.01726.x)
2007
- Collins, P. W. et al. 2007. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109 (5), pp.1870-1877. (10.1182/blood-2006-06-029850)
- Davies, J. A. et al. 2007. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. Journal of Thrombosis and Haemostatis 6 (1), pp.97-103. (10.1111/j.1538-7836.2007.02809.x)
- Gregory, M. et al., 2007. Communicating about haemophilia within the family: the importance of context and of experience. Haemophilia 13 (2), pp.189-198. (10.1111/j.1365-2516.2006.01417.x)
2006
- Bowen, D. J. and Collins, P. W. 2006. Insights into von Willebrand factor proteolysis: clinical implications [Review]. British Journal of Haematology 133 (5), pp.457-467. (10.1111/j.1365-2141.2006.06096.x)
- Cumming, A. et al., 2006. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis 96 , pp.630-641. (10.1160/TH06-07-0383)
- Davies, J. A. et al. 2006. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 109 (7), pp.2840-2846. (10.1182/blood-2006-07-035105)
- Haj, M. A. et al., 2006. Cefotaxime as the potential cause of transient acquired von Willebrand syndrome. European Journal of Haematology 76 (5), pp.440-443. (10.1111/j.0902-4441.2006.t01-1-EJH2386.x)
- Hamilton, M. et al., 2006. Liver haemorrhage in haemophilia - a case report and review of the literature [Case report]. Haemophilia 12 (4), pp.441-443. (10.1111/j.1365-2516.2006.01291.x)
- Hay, C. R. M. et al., 2006. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology 133 (6), pp.591-605. (10.1111/j.1365-2141.2006.06087.x)
2005
- Bowen, D. J. et al. 2005. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology 128 (6), pp.830-836. (10.1111/j.1365-2141.2005.05375.x)
2004
- Bowen, D. J. and Collins, P. W. 2004. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 103 (3), pp.941-947. (10.1182/blood-2003-05-1505)
- Collins, P. W. et al. 2004. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. British Journal of Haematology 124 (1), pp.86-90. (10.1046/j.1365-2141.2003.04731.x)
- Darby, S. C. et al., 2004. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. Journal of Thrombosis and Haemostatis 2 (7), pp.1047-1054. (10.1046/j.1538-7836.2004.00710.x)
- Elliott, J. I. et al., 2004. Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. Thrombosis and Haemostasis 91 (2), pp.412-415.
- Haj, M. et al., 2004. Acquired haemophilia A may be associated with clopidogrel. British Medical Journal (BMJ) 329 (7461), pp.323. (10.1136/bmj.329.7461.323)
- Laffan, M. et al., 2004. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 (3), pp.199-217. (10.1111/j.1365-2516.2004.00894.x)
- Ludlam, C. A. et al., 2004. Gene therapy trials in the UK: is haemophilia a suitable 'model'?. Clinical Medicine 4 (1), pp.54-56. (10.7861/clinmedicine.4-1-54)
- Pasi, K. J. et al., 2004. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 (3), pp.218-231. (10.1111/j.1365-2516.2004.00886.x)
2003
- Brown, S. A. et al., 2003. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?. Journal Of Thrombosis And Haemostasis 1 (8), pp.1714-1717. (10.1046/j.1538-7836.2003.00359.x)
- Smith, J. C. et al. 2003. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. Journal of Clinical Endocrinology & Metabolism 88 (5), pp.2152-2156. (10.1210/jc.2002-021618)
2002
- Brown, S. A. et al., 2002. Factor VIIa induced release of von Willebrand factor from human umbilical vein endothelial cells by a tyrosine kinase dependent pathway. Journal of Thrombosis and Haemostasis 87 , pp.1057-1061.
- Brown, S. A. , Collins, P. W. and Bowen, D. J. 2002. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thrombosis and Haemostasis 87 (6), pp.990-996.
- Clark, S. R. et al. 2002. Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidase-deficient human neutrophils. The Journal of Immunology 169 (10), pp.5889-5896.
- De Brasi, C. D. et al., 2002. The CpG island in intron 22 of the factor VIII gene is predominantly methylated on the X chromosome of human males. Journal of Human Genetics 47 (5), pp.239-242. (10.1007/s100380200032)
2001
- Bowen, D. J. et al. 2001. High concentrations of coagulation factor VIII and thrombosis: Is the factor VIII-binding domain of von Willebrand factor implicated?. British Journal of Haematology 113 (3), pp.655-657. (10.1046/j.1365-2141.2001.02830.x)
2000
- Bowen, D. J. et al. 2000. A new polymorphism in the human factor VIII gene: implications for linkage analysis in haemophilia A and for the evolution of int22h sequences. British Journal of Haematology 111 (2), pp.544-548. (10.1111/j.1365-2141.2000.02373.x)
- Mumford, A. D. et al., 2000. A23187 induced apoptosis and pro-coagulant activity are delayed, but not absent, in lymphocytes from an individual with Scott syndrome. Blood 96 (11), pp.254A-254A.
- Rhys-Dillon, C. et al., 2000. Clinical symptoms and signs do not predict the presence of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection when compared with age and sex matched controls. Blood 96 (11), pp.87B-87B.
- Williams, J. et al., 2000. The topical non steroidal anti-inflammatory drug [NSAID] piroxicam gel has no significant effect on primary platelet related haemostasis in healthy volunteers. Blood 96 (11), pp.70B-71B.
1999
- De Brasi, C. D. et al., 1999. Specific analysis of the intron 22 XbaI polymorphism of the human factor VIII gene using long-distance PCR. British Journal of Haematology 107 (3), pp.566-568. (10.1046/j.1365-2141.1999.01731.x)
- Giddings, J. C. , Phillips, S. A. and Collins, P. W. 1999. Recovery of P-selectin and ICAM-1 expression in passaged cultured human endothelial cells under conditions of flow. Thrombosis and Haemostasis , pp.807-807.
- Hazell, C. et al., 1999. Investigation of the possible link between exposure to air pollution and changes in blood coagulation parameters. Environment International 25 (1), pp.9-16. (10.1016/S0160-4120(98)00091-9)
- Lee, C. A. et al., 1999. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thrombosis and Haemostasis 82 (6), pp.1644-1647.
- MacLean, R. M. et al., 1999. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. British Journal of Haematology 107 (1), pp.210-212. (10.1046/j.1365-2141.1999.01663.x)
- Maclean, R. M. et al., 1999. Markers of platelet activation following DDAVP infusion. Thrombosis and Haemostasis , pp.166-166.
- Maclean, R. M. et al., 1999. Markers of platelet activation following DDAVP infusion in patients with mild haemophilia A and type 1 von Willebrand disease. British Journal of Haematology 105 , pp.47-47.
- Phillips, S. A. et al., 1999. Impaired P-selectin expression associated with defective platelet phospholipid redistribution in a patient with Scott Syndrome. Thrombosis and Haemostasis , pp.796-797.
1998
- Bowen, D. J. et al. 1998. Factor V Leiden (G1691A), the Prothrombin 3’-Untranslated Region Variant (G20210A) and Thermolabile Methylenetetra-hydrofolate Reductase (C677T): A Single Genetic Test Genotypes all Three Loci – Determination of Frequencies in the S. Wales Population. Thrombosis and Haemostasis 79 (5), pp.949-954.
- Clark, Z. E. et al., 1998. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology [Technical Brief]. Clinical Chemistry 44 (11), pp.2360-2362.
- Routledge, P. A. et al. 1998. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism [Case report]. British Journal of Clinical Pharmacology 46 (4), pp.343-346. (10.1046/j.1365-2125.1998.t01-1-00796.x)
- Rye, A. D. et al., 1998. Clinical evaluation of oral anticoagulant monitoring with the TAS near patient test system. British Journal of Haematology 101 , pp.56-56.
1996
- Hopster, D. J. et al., 1996. Renal pathology in haematological malignancies: An autopsy study [Synopsis]. The Journal of Pathology 179 (s1), pp.A32-A32. (10.1002/path.1996.1711790502)
- Jenkins, P. V. et al., 1996. Dominant type 1 vonWillebrand's disease as a result of a deletion of a single codon in exon 28 of the VWF gene [Abstract]. British Journal of Haematology 93 (S2) 1176.
- Noble, K. E. et al., 1996. Monocytes induce E-selectin gene expression in endothelial cells: role of CD11/CD18 and extracellular matrix proteins. European Journal of Immunology 26 (12), pp.2944-2951. (10.1002/eji.1830261221)
1995
- Collins, P. W. et al. 1995. The use of RFVIIA to treat a factor-IX inhibitor following anaphylaxis with factor-IX concentrate. Thrombosis and Haemostasis 73 (6), pp.1029-1029.
- Collins, P. W. et al. 1995. Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1 (4), pp.227-231. (10.1111/j.1365-2516.1995.tb00080.x)
- Collins, P. W. et al. 1995. Clinical-experience of factor-XI deficiency - the use of fresh-frozen plasma and factor-XI concentrate. Thrombosis and Haemostasis 73 (6), pp.1442-1442.
- Jenkins, P. V. et al., 1995. Dominant type 1 von Willebrands disease as a result of a four base pair deletion in exon 28 of the von Willebrand factor gene. Blood 86 (10), pp.265-265.
1994
- Collins, P. W. et al. 1994. Enhanced tissue factor expression due to monocyte - endothelial-cell interaction - modulation by interferon-gamma and the role of ICAM-1. Blood 84 (10), pp.A189-A189.
- Yong, K. L. et al., 1994. Granulocyte-colony-stimulating factor increases neutrophil migration across endothelium without an effect on adhesion - role of PECAM-1. Blood 84 (10), pp.A32-A32.
1993
- Collins, P. W. and Newland, A. C. 1993. Inhibition of VWF release from endothelial-cells by hydroxyethyl starches - a possible cause of acquired vonwillebrand disease [Abstract]. British Journal of Haematology 84 (s1), pp.16-16. (10.1111/j.1365-2141.1993.tb06831.x)
- Collins, P. W. et al. 1993. Bone-marrow transplantation is not associated with increased levels of factor-VIIa [Abstract]. British Journal of Haematology 84 (s1), pp.53-53. (10.1111/j.1365-2141.1993.tb06831.x)
- Jiang, X. R. et al., 1993. Circumvention of P-glycoprotein-mediated multidrug-resistance of human leukemia by a nonimmunosuppressive cyclosporine, SDZ PSC-833 [Abstract]. British Journal of Haematology 84 (s1), pp.30-30. (10.1111/j.1365-2141.1993.tb06831.x)
- Razak, K. et al., 1993. Binding of antibodies to different cd13 epitopes on human myeloid leukemic-cells. International Journal of Oncology 3 (4), pp.749-754. (10.3892/ijo.3.4.749)
- Side, L. et al., 1993. Prognostic value of CD13 CD33 ratio for AML patient survival and the significance of induction of CD13 on AML cells [Abstract]. British Journal of Haematology 84 (s1), pp.2-2. (10.1111/j.1365-2141.1993.tb06831.x)
1992
- Kelsey, S. M. et al., 1992. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients [Erratum]. European Journal of Clinical Microbiology and Infectious Diseases 11 (10), pp.960-960. (10.1007/BF01962389)
1991
- Collins, P. W. et al. 1991. A pilot study using intravenous immunoglobulin for the prevention of infection during remission induction in acute leukaemia. Leukemia and Lymphoma 6 (1), pp.25-29.
1990
- Collins, P. W. , De Lord, C. and Newland, A. C. 1990. Pancoast's tumour due to aspergilloma [Letter]. The Lancet 336 (8730), pp.1595-1595. (10.1016/0140-6736(90)93385-3)
- Collins, P. W. et al. 1990. Invasive aspergillosis in immunosuppressed patients [Letter]. British Medical Journal 301 (6759), pp.1046-1046. (10.1136/bmj.301.6759.1046-c)
Articles
- Aawar, N. et al. 2015. Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials 16 (1), pp.1-11. (10.1186/s13063-015-0670-9)
- Agbani, E. O. et al., 2015. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation 132 (15), pp.1414-1424. (10.1161/CIRCULATIONAHA.114.015036)
- Aldrovandi, M. et al. 2013. Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. Journal of Lipid Research 54 (11), pp.3085-3097. (10.1194/jlr.M041533)
- Aldrovandi, M. et al. 2017. DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biology 11 , pp.663-672. (10.1016/j.redox.2017.01.001)
- Allen-Redpath, K. et al. 2019. Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity. Proceedings of the National Academy of Sciences 116 (16), pp.8038-8047. (10.1073/pnas.1814409116)
- Baaten, C. C. F. M. J. et al., 2018. Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Advances 2 (18), pp.2320-2331. (10.1182/bloodadvances.2017011544)
- Batty, P. et al., 2014. A national survey of immunosuppression strategies for acquired haemophilia A. Haemophilia 21 (1), pp.e73-e76. (10.1111/hae.12547)
- Baudo, F. et al., 2012. Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry. Blood 120 (1), pp.39-46. (10.1182/blood-2012-02-408930)
- Bell, S. F. et al., 2021. The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. International Journal of Obstetric Anesthesia 47 102983. (10.1016/j.ijoa.2021.102983)
- Bell, S. .. , Collis, R. E. and Collins, P. W. 2022. Comparison of haematological indices and transfusion management in severe and massive postpartum haemorrhage: analysis of a two-year national prospective observational study. International Journal of Obstetric Anesthesia 50 103547. (10.1016/j.ijoa.2022.103547)
- Bell, S. F. et al. 2021. Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study. BMC Pregnancy and Childbirth 21 377. (10.1186/s12884-021-03853-y)
- Bell, S. F. et al. 2023. Managing the coagulopathy of postpartum hemorrhage: an evolving role for viscoelastic hemostatic assays. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.03.029)
- Bell, S. F. et al. 2010. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. International Journal of Obstetric Anesthesia 19 (2), pp.218-223. (10.1016/j.ijoa.2009.08.004)
- Bell, S. F. et al. 2025. Relationship between the dual platelet‐inhibited ROTEM ® Sigma FIBTEM assay and Clauss fibrinogen during postpartum haemorrhage. Anaesthesia: Peri-operative medicine, critical care and pain 80 (1), pp.104-106. (10.1111/anae.16455)
- Bell, S. F. et al., 2020. Incidence of postpartum haemorrhage defined by quantitative blood loss measurement: a national cohort. BMC Pregnancy and Childbirth 20 (1) 271. (10.1186/s12884-020-02971-3)
- Bell, S. et al. 2022. The sensitivity and specificity of rotational thromboelastometry (ROTEM) to detect coagulopathy during moderate and severe postpartum haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia 49 103238. (10.1016/j.ijoa.2021.103238)
- Berntorp, E. et al., 2011. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 17 (1), pp.e202-e210. (10.1111/j.1365-2516.2010.02377.x)
- Bjorkman, S. and Collins, P. W. 2013. Measurement of factor VIII pharmacokinetics in routine clinical practice. Journal of Thrombosis and Haemostatis 11 (1), pp.180-182. (10.1111/jth.12055)
- Bjorkman, S. et al., 2010. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostatis 8 (4), pp.730-736. (10.1111/j.1538-7836.2010.03757.x)
- Bjorkman, S. et al., 2012. Population pharmacokinetics of recombinant factor VIII: The relationships of pharmacokinetics to age and body weight. Blood 119 (2), pp.612-618. (10.1182/blood-2011-07-360594)
- Bowen, D. J. et al. 1998. Factor V Leiden (G1691A), the Prothrombin 3’-Untranslated Region Variant (G20210A) and Thermolabile Methylenetetra-hydrofolate Reductase (C677T): A Single Genetic Test Genotypes all Three Loci – Determination of Frequencies in the S. Wales Population. Thrombosis and Haemostasis 79 (5), pp.949-954.
- Bowen, D. J. and Collins, P. W. 2004. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 103 (3), pp.941-947. (10.1182/blood-2003-05-1505)
- Bowen, D. J. and Collins, P. W. 2006. Insights into von Willebrand factor proteolysis: clinical implications [Review]. British Journal of Haematology 133 (5), pp.457-467. (10.1111/j.1365-2141.2006.06096.x)
- Bowen, D. J. et al. 2005. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype. British Journal of Haematology 128 (6), pp.830-836. (10.1111/j.1365-2141.2005.05375.x)
- Bowen, D. J. et al. 2000. A new polymorphism in the human factor VIII gene: implications for linkage analysis in haemophilia A and for the evolution of int22h sequences. British Journal of Haematology 111 (2), pp.544-548. (10.1111/j.1365-2141.2000.02373.x)
- Bowen, D. J. et al. 2001. High concentrations of coagulation factor VIII and thrombosis: Is the factor VIII-binding domain of von Willebrand factor implicated?. British Journal of Haematology 113 (3), pp.655-657. (10.1046/j.1365-2141.2001.02830.x)
- Brown, S. A. et al., 2002. Factor VIIa induced release of von Willebrand factor from human umbilical vein endothelial cells by a tyrosine kinase dependent pathway. Journal of Thrombosis and Haemostasis 87 , pp.1057-1061.
- Brown, S. A. , Collins, P. W. and Bowen, D. J. 2002. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thrombosis and Haemostasis 87 (6), pp.990-996.
- Brown, S. A. et al., 2003. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?. Journal Of Thrombosis And Haemostasis 1 (8), pp.1714-1717. (10.1046/j.1538-7836.2003.00359.x)
- Bruynseels, D. et al. 2016. Commentary on reconstituting fibrinogen concentrate to maintain blinding in a double-blind, randomized trial in an emergency Setting. Journal of Emergency Medicine 28 (1), pp.104-107.e.1. (10.1016/j.jemermed.2015.09.017)
- Bukkems, L. H. et al., 2021. Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease. Blood Advances 5 (5), pp.1513-1522. (10.1182/bloodadvances.2020003891)
- Bury, L. et al., 2020. Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Human Mutation 41 (1), pp.277-290. (10.1002/humu.23927)
- Castoldi, E. et al., 2011. P-MO-061 Identification of two novel TMEM16F mutations in a patient with scott syndrome [Abstract]. Journal of Thrombosis and Haemostatis 9 (s2), pp.77. (10.1111/j.1538-7836.2011.04380_1.x)
- Chalmers, E. A. et al., 2018. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: a national cohort study. Haemophilia 24 (4), pp.641-647. (10.1111/hae.13461)
- Chowdary, P. et al., 2020. Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis. Thrombosis and Haemostasis 120 (05), pp.728-736. (10.1055/s-0040-1709519)
- Chowdary, P. et al., 2018. Retrospective review of a Prothrombin Complex Concentrate (Beriplex P/N) for the management of perioperative bleeding unrelated to oral anticoagulation. Clinical and Applied Thrombosis/Hemostasis 24 (7), pp.1159-1169. (10.1177/1076029617753537)
- Clark, S. R. et al. 2002. Characterization of nitric oxide consumption pathways by normal, chronic granulomatous disease and myeloperoxidase-deficient human neutrophils. The Journal of Immunology 169 (10), pp.5889-5896.
- Clark, S. R. et al. 2013. Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proceedings of the National Academy of Sciences of the United States of America 110 (15), pp.5875-5880. (10.1073/pnas.1222419110)
- Clark, Z. E. et al., 1998. Genotyping method for methylenetetrahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology [Technical Brief]. Clinical Chemistry 44 (11), pp.2360-2362.
- Coakley, M. et al. 2011. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. Journal of Thrombosis and Haemostatis 9 (2), pp.282-292. (10.1111/j.1538-7836.2010.04146.x)
- Collins, P. W. et al. 2017. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. British Journal of Anaesthesia 119 (3), pp.411-421. (10.1093/bja/aex181)
- Collins, P. W. et al. 2017. Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. British Journal of Anaesthesia 119 (3), pp.422-434. (10.1093/bja/aex245)
- Collins, P. W. et al. 2018. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia 24 (1), pp.104-112. (10.1111/hae.13324)
- Collins, P. et al. 2016. Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study. Archives of Disease in Childhood , pp.401-413. (10.1136/archdischild-2015-310196)
- Collins, P. W. , Abdul-Kadir, R. and Thachil, J. 2015. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 14 (1), pp.205-210. (10.1111/jth.13174)
- Collins, P. W. et al. 2019. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. International Journal of Obstetric Anesthesia 37 , pp.106-117. (10.1016/j.ijoa.2018.08.008)
- Collins, P. W. et al. 2018. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 24 (3), pp.344-347. (10.1111/hae.13495)
- Collins, P. W. et al. 2014. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 124 (11), pp.1727-1736. (10.1182/blood-2014-04-567891)
- Collins, P. W. et al. 2021. Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?. Haemophilia 27 (2), pp.192-198. (10.1111/hae.14201)
- Collins, P. W. et al. 2014. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe haemophilia A, 2000-2011. Blood 124 (23), pp.3389-3397. (10.1182/blood-2014-07-580498)
- Collins, P. W. et al. 2025. Acute obstetric coagulopathy is associated with excess plasmin generation and proteolysis of fibrinogen and factor V. Blood Advances 9 (11), pp.2751-2762. (10.1182/bloodadvances.2024015514)
- Collins, P. W. et al. 2014. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 124 (26), pp.3880-3886. (10.1182/blood-2014-05-573055)
- Collins, P. W. 2008. 01 S 01 Overview of acquired haemophilia A [Abstract]. Haemophilia 14 (S2), pp.1. (10.1111/j.1365-2516.2008.01725.x)
- Collins, P. W. 2011. Management of acquired haemophilia A. Journal of Thrombosis and Haemostatis 9 (Supp 1), pp.226-235. (10.1111/j.1538-7836.2011.04309.x)
- Collins, P. W. 2012. Personalized prophylaxis. Haemophilia 18 (s4), pp.131-135. (10.1111/j.1365-2516.2012.02838.x)
- Collins, P. W. 2010. Pharmacokinetic approaches to prophylaxis [Abstract]. Haemophilia 16 (2), pp.396. (10.1111/j.1365-2516.2010.02182.x)
- Collins, P. W. et al. 2010. Announcement: Non-malignant haematology research in the UK: looking forward to new opportunities. British Journal of Haematology 150 (6), pp.732-736. (10.1111/j.1365-2141.2010.08384.x)
- Collins, P. W. et al. 2010. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes 3 161. (10.1186/1756-0500-3-161)
- Collins, P. W. et al. 2012. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood 120 (1), pp.47-55. (10.1182/blood-2012-02-409185)
- Collins, P. W. et al. 2010. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostatis 8 (2), pp.269-275. (10.1111/j.1538-7836.2009.03703.x)
- Collins, P. W. et al. 2009. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostatis 7 (3), pp.413-420. (10.1111/j.1538-7836.2008.03270.x)
- Collins, P. W. et al. 2008. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 14 (s3), pp.49-55. (10.1111/j.1365-2516.2008.01745.x)
- Collins, P. W. et al. 2013. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)[note]. British Journal of Haematology 160 (2), pp.153-170. (10.1111/bjh.12091)
- Collins, P. W. et al. 2013. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. British Journal of Haematology 162 (6), pp.758-773. (10.1111/bjh.12463)
- Collins, P. W. et al. 2008. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 14 (4), pp.685-696. (10.1111/j.1365-2516.2008.01757.x)
- Collins, P. W. , De Lord, C. and Newland, A. C. 1990. Pancoast's tumour due to aspergilloma [Letter]. The Lancet 336 (8730), pp.1595-1595. (10.1016/0140-6736(90)93385-3)
- Collins, P. W. et al. 2007. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109 (5), pp.1870-1877. (10.1182/blood-2006-06-029850)
- Collins, P. W. et al. 2010. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. Journal of Thrombosis and Haemostatis 8 (1), pp.83-89. (10.1111/j.1538-7836.2009.03650.x)
- Collins, P. W. et al. 1995. The use of RFVIIA to treat a factor-IX inhibitor following anaphylaxis with factor-IX concentrate. Thrombosis and Haemostasis 73 (6), pp.1029-1029.
- Collins, P. W. et al. 2011. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17 (1), pp.2-10. (10.1111/j.1365-2516.2010.02370.x)
- Collins, P. W. et al. 1995. Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate. Haemophilia 1 (4), pp.227-231. (10.1111/j.1365-2516.1995.tb00080.x)
- Collins, P. W. et al. 1990. Invasive aspergillosis in immunosuppressed patients [Letter]. British Medical Journal 301 (6759), pp.1046-1046. (10.1136/bmj.301.6759.1046-c)
- Collins, P. W. et al. 1995. Clinical-experience of factor-XI deficiency - the use of fresh-frozen plasma and factor-XI concentrate. Thrombosis and Haemostasis 73 (6), pp.1442-1442.
- Collins, P. W. et al. 2004. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. British Journal of Haematology 124 (1), pp.86-90. (10.1046/j.1365-2141.2003.04731.x)
- Collins, P. W. et al. 2009. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostatis 7 (5), pp.787-794. (10.1111/j.1538-7836.2009.03332.x)
- Collins, P. W. et al. 2012. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. Journal of Thrombosis and Haemostatis 10 (11), pp.2305-2312. (10.1111/jth.12000)
- Collins, P. W. and Newland, A. C. 1993. Inhibition of VWF release from endothelial-cells by hydroxyethyl starches - a possible cause of acquired vonwillebrand disease [Abstract]. British Journal of Haematology 84 (s1), pp.16-16. (10.1111/j.1365-2141.1993.tb06831.x)
- Collins, P. W. and Percy, C. L. 2010. Advances in the understanding of acquired haemophilia A: implications for clinical practice. British Journal of Haematology 148 (2), pp.183-194. (10.1111/j.1365-2141.2009.07915.x)
- Collins, P. W. et al. 1994. Enhanced tissue factor expression due to monocyte - endothelial-cell interaction - modulation by interferon-gamma and the role of ICAM-1. Blood 84 (10), pp.A189-A189.
- Collins, P. W. et al. 1993. Bone-marrow transplantation is not associated with increased levels of factor-VIIa [Abstract]. British Journal of Haematology 84 (s1), pp.53-53. (10.1111/j.1365-2141.1993.tb06831.x)
- Collins, P. W. et al. 1991. A pilot study using intravenous immunoglobulin for the prevention of infection during remission induction in acute leukaemia. Leukemia and Lymphoma 6 (1), pp.25-29.
- Costa, D. O. et al. 2025. Circulating membrane aminophospholipids contribute to thrombotic risk in rheumatoid arthritis.. Journal of Lipid Research 66 (7) 100842. (10.1016/j.jlr.2025.100842)
- Cumming, A. et al., 2006. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Journal of Thrombosis and Haemostasis 96 , pp.630-641. (10.1160/TH06-07-0383)
- Curry, N. S. et al., 2018. The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology 182 (6), pp.789-806. (10.1111/bjh.15524)
- Dale, M. et al. 2022. What is the economic cost of providing an all Wales postpartum haemorrhage quality improvement initiative (OBS Cymru)? A cost-consequences comparison with standard care. PharmacoEconomics - Open 6 , pp.847-857. (10.1007/s41669-022-00362-2)
- Darby, S. C. et al., 2004. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. Journal of Thrombosis and Haemostatis 2 (7), pp.1047-1054. (10.1046/j.1538-7836.2004.00710.x)
- Davies, J. A. et al. 2006. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 109 (7), pp.2840-2846. (10.1182/blood-2006-07-035105)
- Davies, J. A. et al. 2007. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. Journal of Thrombosis and Haemostatis 6 (1), pp.97-103. (10.1111/j.1538-7836.2007.02809.x)
- Davies, J. A. et al. 2012. von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom [Letter]. Haemophilia 18 (3), pp.e79-e81. (10.1111/j.1365-2516.2012.02782.x)
- De Brasi, C. D. et al., 1999. Specific analysis of the intron 22 XbaI polymorphism of the human factor VIII gene using long-distance PCR. British Journal of Haematology 107 (3), pp.566-568. (10.1046/j.1365-2141.1999.01731.x)
- De Brasi, C. D. et al., 2002. The CpG island in intron 22 of the factor VIII gene is predominantly methylated on the X chromosome of human males. Journal of Human Genetics 47 (5), pp.239-242. (10.1007/s100380200032)
- De Lloyd, L. et al. 2011. Standard haemostatic tests following major obstetric haemorrhage. International Journal of Obstetric Anesthesia 20 (2), pp.135-141. (10.1016/j.ijoa.2010.12.002)
- de Lloyd, L. et al. 2023. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. Journal of Thrombosis and Haemostasis 21 (4), pp.862-879. (10.1016/j.jtha.2022.11.036)
- di Mambro, A. J. et al., 2011. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53 (4), pp.1316-1322. (10.1002/hep.24159)
- Diguisto, C. et al., 2024. Management and outcomes of women with low fibrinogen concentration during pregnancy or immediately postpartum: A UK national population‐based cohort study. Acta Obstetricia et Gynecologica Scandinavica 103 (7), pp.1339-1347. (10.1111/aogs.14828)
- Dixon, P. H. et al., 2022. GWAS meta-analysis of intrahepatic cholestasis of pregnancy implicates multiple hepatic genes and regulatory elements. Nature Communications 13 (1) 4840. (10.1038/s41467-022-29931-z)
- Elliott, J. I. et al., 2004. Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. Thrombosis and Haemostasis 91 (2), pp.412-415.
- Elsmore, A. et al., 2024. The OBS UK Dashboard: an interactive tool for representative trial site selection to facilitate equality and diversity in maternity research. Trials 25 629. (10.1186/s13063-024-08487-x)
- Fischer, K. et al., 2016. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 14 (5), pp.1105-1109. (10.1111/jth.13298)
- Fletcher, S. J. et al., 2015. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects. The Journal of Clinical Investigation 125 (9), pp.3600-3605. (10.1172/JCI80347)
- Fransen Van De Putte, D. et al., 2012. Cardiovascular disease history and risk factors in hemophilia patients [Abstract]. Haemophilia 18 (s3), pp.4-5. (10.1111/j.1365-2516.2012.02820.x)
- Fransen van de Putte, D. E. et al., 2013. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis 109 (01), pp.16-23. (10.1160/TH12-05-0332)
- Giddings, J. C. , Phillips, S. A. and Collins, P. W. 1999. Recovery of P-selectin and ICAM-1 expression in passaged cultured human endothelial cells under conditions of flow. Thrombosis and Haemostasis , pp.807-807.
- Gorman, K. M. et al., 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104 (5), pp.948-956. (10.1016/j.ajhg.2019.03.005)
- Green, L. et al., 2016. The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. BJOG: An International Journal of Obstetrics & Gynaecology 123 (13), pp.2164-2170. (10.1111/1471-0528.13831)
- Green, L. et al., 2016. The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. British Journal of Haematology 172 (4), pp.616-624. (10.1111/bjh.13864)
- Gregory, M. et al., 2007. Communicating about haemophilia within the family: the importance of context and of experience. Haemophilia 13 (2), pp.189-198. (10.1111/j.1365-2516.2006.01417.x)
- Haj, M. et al., 2004. Acquired haemophilia A may be associated with clopidogrel. British Medical Journal (BMJ) 329 (7461), pp.323. (10.1136/bmj.329.7461.323)
- Haj, M. A. et al., 2006. Cefotaxime as the potential cause of transient acquired von Willebrand syndrome. European Journal of Haematology 76 (5), pp.440-443. (10.1111/j.0902-4441.2006.t01-1-EJH2386.x)
- Hajeyah, A. A. et al. 2024. Phosphatidylthreonine is a procoagulant lipid detected in human blood and elevated in coronary artery disease.. Journal of Lipid Research 65 (1) 100484. (10.1016/j.jlr.2023.100484)
- Hamilton, M. et al., 2006. Liver haemorrhage in haemophilia - a case report and review of the literature [Case report]. Haemophilia 12 (4), pp.441-443. (10.1111/j.1365-2516.2006.01291.x)
- Hay, C. R. M. et al., 2015. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 21 (2), pp.219-226. (10.1111/hae.12563)
- Hay, C. R. M. et al., 2017. The haemtrack home therapy reporting system: design, implementation, strengths and weaknesses: a report from UK Haemophilia Centre Doctors Organisation. Haemophilia 23 (5), pp.728-735. (10.1111/hae.13287)
- Hay, C. R. M. et al., 2006. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology 133 (6), pp.591-605. (10.1111/j.1365-2141.2006.06087.x)
- Hay, C. R. M. et al., 2011. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 117 (23), pp.6367-6370. (10.1182/blood-2010-09-308668)
- Hazell, C. et al., 1999. Investigation of the possible link between exposure to air pollution and changes in blood coagulation parameters. Environment International 25 (1), pp.9-16. (10.1016/S0160-4120(98)00091-9)
- Hazendonk, H. C. A. M. et al., 2018. Perioperative replacement therapy in haemophilia B: an appeal to "B" more precise. Haemophilia 24 (4), pp.611-618. (10.1111/hae.13469)
- Hazendonk, H. et al., 2018. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?. Blood Reviews 32 (4), pp.265-271. (10.1016/j.blre.2018.01.001)
- Heurich-Sevcenco, M. et al. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145 , pp.84-92. (10.1016/j.thromres.2016.07.017)
- Hinz, C. et al. 2016. Human platelets utilize cycloxygenase-1 to generate dioxolane A3, a neutrophil activating eicosanoid. Journal of Biological Chemistry 291 (26), pp.13448-13464. (10.1074/jbc.M115.700609)
- Hopster, D. J. et al., 1996. Renal pathology in haematological malignancies: An autopsy study [Synopsis]. The Journal of Pathology 179 (s1), pp.A32-A32. (10.1002/path.1996.1711790502)
- Huth-Kuhne, A. et al., 2009. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 94 (4), pp.566-575. (10.3324/haematol.2008.001743)
- Iorio, A. et al., 2017. Estimating and interpreting individual patients' pharmacokinetic profiles in persons with Hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostatis 15 (12), pp.2461-2465. (10.1111/jth.13867)
- Iorio, A. et al., 2018. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2 (3), pp.535-548. (10.1002/rth2.12106)
- Jenkins, P. V. et al., 1995. Dominant type 1 von Willebrands disease as a result of a four base pair deletion in exon 28 of the von Willebrand factor gene. Blood 86 (10), pp.265-265.
- Jenkins, P. V. et al., 1996. Dominant type 1 vonWillebrand's disease as a result of a deletion of a single codon in exon 28 of the VWF gene [Abstract]. British Journal of Haematology 93 (S2) 1176.
- Jiang, X. R. et al., 1993. Circumvention of P-glycoprotein-mediated multidrug-resistance of human leukemia by a nonimmunosuppressive cyclosporine, SDZ PSC-833 [Abstract]. British Journal of Haematology 84 (s1), pp.30-30. (10.1111/j.1365-2141.1993.tb06831.x)
- Johnson, B. et al., 2016. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica 101 (10), pp.1170-1179. (10.3324/haematol.2016.146316)
- Jones, R. M. et al., 2016. Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia 71 (6), pp.648-656. (10.1111/anae.13448)
- Kelsey, S. M. et al., 1992. Teicoplanin plus ciprofloxacin versus gentamicin plus piperacillin in the treatment of febrile neutropenic patients [Erratum]. European Journal of Clinical Microbiology and Infectious Diseases 11 (10), pp.960-960. (10.1007/BF01962389)
- Kemp, A. M. et al. 2015. Patterns of bruising in preschool children - a longitudinal study. Archives of Disease in Childhood 100 (5), pp.426-431. (10.1136/archdischild-2014-307120)
- Kemp, A. M. et al. 2014. Bruising in children who are assessed for suspected physical abuse. Archives of Disease in Childhood 99 , pp.108-113. (10.1136/archdischild-2013-304339)
- Kemp, A. M. et al. 2021. Can TEN4 distinguish bruises from abuse, inherited bleeding disorders or accidents?. Archives of Disease in Childhood 106 (8), pp.774-779. (10.1136/archdischild-2020-320491)
- Khanum, F. et al., 2014. Characterization of F8 defects in haemophilia A in Pakistan: investigation of correlation between mutation type and the in vitro thrombin generation assay. Haemophilia 20 (2), pp.287-293. (10.1111/hae.12272)
- Klamroth, R. et al., 2021. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood 137 (13), pp.1818–1827. (10.1182/blood.2020005673)
- Kloosterman, F. R. et al., 2022. The bleeding phenotype in people with nonsevere hemophilia. Blood Advances 6 (14), pp.4256-4265. (10.1182/bloodadvances.2022007620)
- Knoebl, P. et al., 2012. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostatis 10 (4), pp.622-631. (10.1111/j.1538-7836.2012.04654.x)
- Koopman, S. F. et al., 2024. A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B. British Journal of Clinical Pharmacology 90 (1), pp.220-231. (10.1111/bcp.15881)
- Krishnaswamy, S. et al., 2021. Illustrated state-of-the-art capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis 5 (5) e12532. (10.1002/rth2.12532)
- Laffan, M. et al., 2004. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 (3), pp.199-217. (10.1111/j.1365-2516.2004.00894.x)
- Lane, J. et al., 2013. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics 22 (9), pp.1903-1910. (10.1093/hmg/ddt033)
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10 (507) eaan2787. (10.1126/scisignal.aan2787)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2 (1)(10.12688/wellcomeopenres.10308.1)
- Lee, C. A. et al., 1999. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thrombosis and Haemostasis 82 (6), pp.1644-1647.
- Lilley, G. et al., 2015. Measurement of blood loss during postpartum haemorrhage. International Journal of Obstetric Anesthesia 24 (1), pp.8-14. (10.1016/j.ijoa.2014.07.009)
- Lock, J. et al., 2016. Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia 22 (1) e1. (10.1111/hae.12851)
- Ludlam, C. A. et al., 2004. Gene therapy trials in the UK: is haemophilia a suitable 'model'?. Clinical Medicine 4 (1), pp.54-56. (10.7861/clinmedicine.4-1-54)
- MacLean, R. M. et al., 1999. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. British Journal of Haematology 107 (1), pp.210-212. (10.1046/j.1365-2141.1999.01663.x)
- Maclean, R. M. et al., 1999. Markers of platelet activation following DDAVP infusion. Thrombosis and Haemostasis , pp.166-166.
- Maclean, R. M. et al., 1999. Markers of platelet activation following DDAVP infusion in patients with mild haemophilia A and type 1 von Willebrand disease. British Journal of Haematology 105 , pp.47-47.
- Mahdi, A. J. , Obaji, S. and Collins, P. W. 2015. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. British Journal of Haematology 169 (6), pp.768-776. (10.1111/bjh.13360)
- Mathias, M. C. et al., 2018. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia 24 (6), pp.896-901. (10.1111/hae.13551)
- Mattheij, N. J. et al., 2016. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling and swelling. Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde 41 (3), pp.207-208.
- Mattheij, N. J. A. et al., 2016. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. The FASEB Journal 30 (2), pp.727-737. (10.1096/fj.15-280446)
- Mauguière, F. A. L. et al., 2016. Toward understanding the roaming mechanism in H + MgH → Mg + HH reaction. Journal of Physical Chemistry A 120 (27), pp.5145-5154. (10.1021/acs.jpca.6b00682)
- Meher, S. et al., 2018. Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: An International Journal of Obstetrics & Gynaecology (10.1111/1471-0528.15335)
- Moore, G. et al., 2008. 31 FP 05 Management of von Willebrand disease in the peripartum period - a UK based survey [Abstract]. Haemophilia 14 (S2), pp.155. (10.1111/j.1365-2516.2008.01726.x)
- Morgan, B. et al. 2025. Pro-Coagulant Lipids in Physiological Ratios Found in the Activated Platelet Membrane Do Not Impact Clot Structure or Fibrinolysis in Purified Assays. Journal of Blood Medicine 16 , pp.509-521. (10.2147/jbm.s527558)
- Mumford, A. D. et al., 2000. A23187 induced apoptosis and pro-coagulant activity are delayed, but not absent, in lymphocytes from an individual with Scott syndrome. Blood 96 (11), pp.254A-254A.
- Noble, K. E. et al., 1996. Monocytes induce E-selectin gene expression in endothelial cells: role of CD11/CD18 and extracellular matrix proteins. European Journal of Immunology 26 (12), pp.2944-2951. (10.1002/eji.1830261221)
- Obaji, S. et al. 2016. Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia 22 (2), pp.285-291. (10.1111/hae.12811)
- Obaji, S. et al. 2015. Selective angiographic embolization for recurrent elbow and knee haemarthroses in haemophilia: a retrospective case series. Haemophilia 21 (3), pp.e226-e228. (10.1111/hae.12629)
- Oh, M. et al. 2010. The effect of reduced sampling time points in a population pharmacokinetic model of ADVATE in pediatric and adult patients with hemophilia A [Abstract]. Haemophilia -Oxford- 16 (S4), pp.38-39. (10.1111/j.1365-2516.2010.02283.x)
- Olasupo, O. O. et al., 2021. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Cochrane Library 2021 (8) CD014201. (10.1002/14651858.CD014201)
- Pasi, K. J. et al., 2004. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10 (3), pp.218-231. (10.1111/j.1365-2516.2004.00886.x)
- Percy, C. L. et al., 2015. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass. Blood Coagulation and Fibrinolysis 26 (4), pp.357-367. (10.1097/MBC.0000000000000243)
- Percy, C. L. et al. 2009. Laboratory monitoring of Scott Syndrome. British Journal of Haematology 149 (6), pp.803. (10.1111/j.1365-2141.2009.07935.x)
- Peyvandi, F. et al., 2017. Minimal dataset for post-registration surveillance of new drugs in haemophilia: communication from the SSC or the ISTH. Journal of Thrombosis and Haemostatis 15 (9), pp.1878-1881. (10.1111/jth.13762)
- Phillips, S. A. et al., 1999. Impaired P-selectin expression associated with defective platelet phospholipid redistribution in a patient with Scott Syndrome. Thrombosis and Haemostasis , pp.796-797.
- Pipe, S. W. et al., 2024. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood 14 , pp.1355-1364. (10.1182/blood.2023021832)
- Pleines, I. et al., 2017. Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. The Journal of Clinical Investigation 127 (3), pp.814-829. (10.1172/JCI86154)
- Powell, E. et al., 2022. Introduction of standardized, cumulative quantitative measurement of blood loss into routine maternity care. Journal of Maternal-Fetal and Neonatal Medicine 35 (8), pp.1491-1497. (10.1080/14767058.2020.1759534)
- Preijers, T. et al., 2018. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostatis 16 (11), pp.2196-2207. (10.1111/jth.14292)
- Protty, M. B. et al. 2022. The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis. Open Biology 12 (4) 210318. (10.1098/rsob.210318)
- Protty, M. B. et al. 2024. Thrombin generation is associated with extracellular vesicle and leukocyte lipid membranes in atherosclerotic cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 44 (9), pp.2038-2052. (10.1161/ATVBAHA.124.320902)
- Protty, M. B. et al. 2025. Aspirin modulates generation of procoagulant phospholipids in cardiovascular disease, by regulating LPCAT3.. Journal of Lipid Research 66 (1) 100727. (10.1016/j.jlr.2024.100727)
- Rai, T. et al., 2025. Managing obstetric bleeding in Wales: a qualitative evaluation of the OBS Cymru care bundle using normalisation process theory. PLoS One 20 (4) e0320754. (10.1371/journal.pone.0320754)
- Razak, K. et al., 1993. Binding of antibodies to different cd13 epitopes on human myeloid leukemic-cells. International Journal of Oncology 3 (4), pp.749-754. (10.3892/ijo.3.4.749)
- Rhys-Dillon, C. et al., 2000. Clinical symptoms and signs do not predict the presence of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection when compared with age and sex matched controls. Blood 96 (11), pp.87B-87B.
- Roberts, T. C. D. et al., 2021. Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia 47 103192. (10.1016/j.ijoa.2021.103192)
- Rosas, M. et al. 2020. The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles. PLoS ONE 15 (10) e0240189. (10.1371/journal.pone.0240189)
- Routledge, P. A. et al. 1998. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism [Case report]. British Journal of Clinical Pharmacology 46 (4), pp.343-346. (10.1046/j.1365-2125.1998.t01-1-00796.x)
- Rye, A. D. et al., 1998. Clinical evaluation of oral anticoagulant monitoring with the TAS near patient test system. British Journal of Haematology 101 , pp.56-56.
- Saunders, C. et al., 2013. Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma. Vox Sanguinis 105 (1), pp.1-10. (10.1111/vox.12013)
- Schöchl, H. et al., 2017. Theoretical modeling of coagulation management with therapeutic plasma or prothrombin complex concentrate. Anesthesia and Analgesia 125 (5), pp.1471-1474. (10.1213/ANE.0000000000002410)
- Scott, M. J. et al., 2019. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia -Oxford- 25 (2), pp.205-212. (10.1111/hae.13616)
- Shapiro, A. et al., 2009. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opinion on Biological Therapy 9 (3), pp.273-283. (10.1517/14712590902729392)
- Side, L. et al., 1993. Prognostic value of CD13 CD33 ratio for AML patient survival and the significance of induction of CD13 on AML cells [Abstract]. British Journal of Haematology 84 (s1), pp.2-2. (10.1111/j.1365-2141.1993.tb06831.x)
- Simeoni, I. et al., 2016. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 127 (23), pp.2791-2803. (10.1182/blood-2015-12-688267)
- Slatter, D. A. et al. 2018. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight 3 (6) e98459. (10.1172/jci.insight.98459)
- Smith, J. C. et al. 2003. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. Journal of Clinical Endocrinology & Metabolism 88 (5), pp.2152-2156. (10.1210/jc.2002-021618)
- Solari, F. A. et al., 2016. Combined quantification of the global proteome, phosphoproteome, and proteolytic cleavage to characterize altered platelet functions in the human Scott syndrome. Molecular & Cellular Proteomics 15 (10), pp.3154-3169. (10.1074/mcp.M116.060368)
- Stockley, J. et al., 2013. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood 122 (25), pp.4090-4093. (10.1182/blood-2013-06-506873)
- Stritt, S. et al., 2016. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood 127 (23), pp.2903-2914. (10.1182/blood-2015-10-675629)
- Sutherland, M. S. et al., 2009. A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3. Blood 114 (5), pp.1091-1098. (10.1182/blood-2008-08-173278)
- Swieringa, F. et al., 2016. Platelet control of fibrin distribution and microelasticity in thrombus formation under flow. Arteriosclerosis Thrombosis and Vascular Biology 36 (4), pp.692-699. (10.1161/ATVBAHA.115.306537)
- Tengborn, L. et al., 2012. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG: An International Journal of Obstetrics & Gynaecology 119 (12), pp.1529-1537. (10.1111/j.1471-0528.2012.03469.x)
- Thomas, C. P. et al. 2014. Identification and quantification of aminophospholipid molecular species on the surface of apoptotic and activated cells. Nature Protocols 9 (1), pp.51-63. (10.1038/nprot.2013.163)
- Thomas, C. P. et al. 2010. Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. Journal of Biological Chemistry 285 (10), pp.6891-6903. (10.1074/jbc.M109.078428)
- Tiede, A. et al., 2020. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A. Haemophilia 26 (1), pp.47-55. (10.1111/hae.13878)
- Torabi, F. et al., 2022. Risk of thrombocytopenic, haemorrhagic and thromboembolic disorders following COVID-19 vaccination and positive test: a self-controlled case series analysis in Wales. Scientific Reports 12 16406. (10.1038/s41598-022-20118-6)
- Trickey, R. C. et al. 2017. Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development post-surgery. Haemophilia 23 (3), pp.e234-e235. (10.1111/hae.13216)
- Turro, E. et al., 2016. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Science Translational Medicine 8 (328) 328ra30. (10.1126/scitranslmed.aad7666)
- Uderhardt, S. et al., 2017. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis and thrombotic disease. Journal of Experimental Medicine 214 (7), pp.2121-2138. (10.1084/jem.20161070)
- Valentino, L. A. et al., 2016. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 22 (4), pp.514-520. (10.1111/hae.12905)
- Van Der Valk, P. et al., 2022. Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances 6 (3), pp.902-908. (10.1182/bloodadvances.2021005260)
- Van Netten, C. et al., 2025. Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis. BMJ Open 15 (5) e101255. (10.1136/bmjopen-2025-101255)
- Wall, C. et al., 2023. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO). Haemophilia 29 (3)(10.1111/hae.14762)
- Wall, C. et al., 2025. Emicizumab utilisation, safety and outcomes in people with severe haemophilia and no inhibitors: Three years follow-up. A report from the UK Haemophilia Centre Doctors’ Organisation. Research and Practice in Thrombosis and Haemostasis 9 (6) 103164. (10.1016/j.rpth.2025.103164)
- Whitworth, J. et al., 2018. Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes. American Journal of Human Genetics 103 (1), pp.3-18. (10.1016/j.ajhg.2018.04.013)
- Wielders, S. J. H. et al., 2009. Absence of platelet-dependent fibrin formation in a patient with Scott syndrome. Thrombosis and Haemostasis 102 (1), pp.76-82. (10.1160/TH08-11-0719)
- Williams, J. et al., 2000. The topical non steroidal anti-inflammatory drug [NSAID] piroxicam gel has no significant effect on primary platelet related haemostasis in healthy volunteers. Blood 96 (11), pp.70B-71B.
- Yong, K. L. et al., 1994. Granulocyte-colony-stimulating factor increases neutrophil migration across endothelium without an effect on adhesion - role of PECAM-1. Blood 84 (10), pp.A32-A32.
- Young, G. et al., 2016. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thrombosis Research 141 , pp.69-76. (10.1016/j.thromres.2016.02.030)
- Zwagemaker, A. et al., 2023. Little discrepancy between one-stage and chromogenic FVIII/IX assays in a large international cohort of persons with non-severe hemophilia A and B. Journal of Thrombosis and Haemostasis 21 (4), pp.850-861. (10.1016/j.jtha.2022.11.040)
Book sections
- Collins, P. W. and Thachil, J. 2025. Acquired coagulation disorders. In: Mead, A. J. et al., Hoffbrand's Postgraduate Haematology. Wiley. , pp.829-847. (10.1002/9781119706687.ch43)
Monographs
- Bell, S. F. et al. 2021. Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study (October 11, 2020). Working paper. SSRN: SSRN. Available at: http://doi.org/10.2139/ssrn.3746928.
Research
Research overview
My research interests focus on blood clotting. This includes studies into the diagnosis and treatment of inherited and acquired bleeding and laboratory studies into understanding of mechanisms of how blood clots.
Research description
Mechanisms of coagulation
I work in a group of basic scientists and clinicians jointly led with Professor O’Donnell that is investigating mechanisms of blood coagulation. Projects include the role of oxidised phospholipids in supporting blood clotting reactions, mechanisms underlying the antiphospholipid syndrome, the effects of oxidised phospholipids in cardiovascular disease and how phospholipids support tissue factor function. This work is support by project and program grants from Wellcome and The British Heart Foundation and a clinical training fellowship from BHF.
In related studies Dr Meike Heurich is investigating the interaction and crosstalk between the complement system and coagulation supported by a NISCHR fellowship. The work is studying how two important innate defence mechanisms interact during normal physiology and disease processes.
Clinical studies
Bleeding at the time of childbirth
I collaborate with colleagues in obstetric and anaesthesia investigating mechanisms and treatment of bleeding at the time of childbirth. A number of our studies have been completed, for example OBS1 (obstetric bleeding study 1) and suggest an important role for the blood clotting factor fibrinogen in controlling bleeding. These studies have led on to our group being awarded funding for a multicentre, randomised, blinded study of fibrinogen versus placebo in the management of postpartum haemorrhage (OBS2). This work is being done in collaboration with Professor Judith Hall as part of the Critical Illness Research Group at Cardiff University and is very well supported by the South East Wales Trials Unit.
Acquired haemophilia A
I have a longstanding interest in the auto-immune disease acquired haemophilia A which presents with sudden onset of severe bleeding. It is caused by the development of an inhibitory antibody to coagulation factor VIII. Along with colleagues in a Europe-wide collaboration the cause and treatment of this disorder is being investigated through the European Acquired Haemophilia Registry (EACH2).
Factor VIII pharmacokinetics (PK) and the treatment of haemophilia A
I work with an international collaborative group investigating the role of factor VIII PK in the management of haemophilia, especially in the context of prophylaxis. A clinical trial is underway to evaluate the role of PK in patient management. The work is being extended to the measurement of factor VIII PK in the context of factor VIII inhibitors.
A further project with Dr Derrick Bowen is investigating mechanisms that predispose patients with severe haemophilia A to haemophilic arthropathy.
Bruising in children with and without inherited bleeding disorders
In collaboration with the Department of Child Health (Professor Alison Kemp and Dr Sabine Maguire) and paediatric haematologists in Edinburgh, Glasgow, Great Ormond Street, Newcastle and Toronto I am investigating the pattern of bruising in children with and without inherited bleeding disorders and comparing this to children who have suffered physical abuse. The work aims to improve the diagnosis of physical abuse and reduced the chance of misdiagnosis of bleeding disorders.
Clinical trials
The haemophilia centre in Cardiff is an active site for clinical trials in the field of inherited bleeding disorders.
Teaching
I teach medical and dental students about disorders of thrombosis and haemostasis through a programme of lectures.
Biography
Qualifications:
BA Hons Cantab, MBBS, MD (Lond), FRCP, FRCpath
